In contrast to peptides and unmodified proteins, T-activated® proteins are processed and cross-presented via both the exogenous and endogenous pathway by functional antigen-presenting cells, thus mimicking a natural infection very closely. In addition, T-activated® proteins allow a more efficient and HLA antigen-independent stimulation of a broad spectrum of clinically-relevant subpopulations of immune effector cells including mature T helper cells, cytotoxic T cells, natural killer (NK) and NKT-like cells.

T-activation process exemplified by Lophius’ T-Track® CMV process

The T-activation technology has been successfully deployed and shown its potential in the T-Track® CMV diagnostic kit. Potential future diagnostic applications of the T-activation approach include supplementary diagnostic solutions for other pathogens in transplantation medicine such as Epstein-Barr virus, Adenovirus, Human Polyomavirus 1 or Aspergillus. Another opportunity to leverage the potential of the technology are specialty diagnostics, like for Lyme disease or to guide cancer immunotherapy.